**Supplemental Table 1. Baseline characteristics of HDV Ab (+), HDV “confirmed” versus HDV “cleared”**

|  |  |  |  |
| --- | --- | --- | --- |
|  | HDV clearedHDAb (+), Confirmation (-) a(n = 22) | HDV confirmedHDAb (+),Confirmation (+) b(n = 91) | ***P*** |
| Age, years | 43 (12.0) | 41 (12.0) | 0.37 |
| Gender  Male Female | 12 (54.6)10 (45.4) | 59 (64.8)32 (35.2) | 0.37 |
| Race White Black Asian Other | 4 (18.2)6 (27.3)12 (54.5)0 (0.0) | 34 (37.4)16 (17.6)39 (42.9)2 (2.1) | 0.090.30.330.48 |
| **HCV (+), %** | **0.0 \*** | **1.8 \*** | **0.74** |
| **HIV (+), %** | **0.0**  | **1.1** | **0.64** |
| **HBeAg (+), %** | **9.1** | **10.0** | **0.9** |
| **HBeAb (+), %** | **77.3** | **80.0** | **0.78** |
| **HDV endemic country of origin, %** | **63.6** | **65.9** | **0.85** |
| **IVDU (+), %** | **9.1** | **11.0** | **0.8** |
| Anti-nucleo(s)tide therapy, % | **18.2** | **11.0** | **0.36** |
| **Laboratory**  |  |  |  |
|  **ALP (U/L)** | **74.0 (22.7)** | **92.3 (43.2)** | **0.057** |
|  **AST (U/L)** | **38.0 (35.2)** | **82.7 (81.2)** | **0.013** |
|  **ALT (U/L)** | **50.5 (58.0)** | **117.9 (118.2)** | **0.011** |
|  **Total bilirubin (mg/dL)** | **0.6 (0.3)** | **0.9 (1.6)** | **0.4** |
|  **GGT (U/L)** | **34.3 (20.8)** | **71.3 (79.9)** | **0.034** |
|  **Albumin (g/dL)** | **4.3 (0.3)** | **4.1 (0.4)** | **0.024** |
|  **PT (seconds)** | **14.0 (1.0)** | **14.4 (1.5)** | **0.23** |
|  **PLT (K/µL)**  | **213.6 (70.5)** | **167.6 (68.3)** | **0.0057** |
|  **APRI** | **0.6 (0.7)** | **1.9 (2.8)** | **0.035** |
|  **FIB-4** | **1.4 (1.2)** | **2.7 (3.3)** | **0.079** |

**Values expressed as mean (standard deviation) or n (%) unless otherwise stated. a = negative confirmation testing (HDV-RNA PCR); b = confirmed HDV cases with detection of HDV-RNA or HDAg staining on liver biopsy; \*= >10% missing values**

Abbreviations: HDV, hepatitis D virus; HDAb, hepatitis D virus antibody; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HBeAg, hepatitis B e-antigen; HBeAb, hepatitis B e-antibody; IVDU, intravenous drug user; **ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; PT, prothrombin time; PLT, platelet count; APRI, AST-to-platelet ratio index; FIB-4, fibrosis-4 score**